On October 16, 2026, RoboSense (02498.HK) edged up. As of 14:33, it was quoted at HK$14.75, up 1.03%.
SMIC (00981.HK) rose 0.67% to HKD 52.500. TSMC's third-quarter revenue rose 50.9% year on year; ASML posted record quarterly net sales of EUR 11.662 billion.
UBTECH ROBOTICS (09880.HK) rose 4.55% to HKD 65.500. U1 robots began small-batch deliveries, a cheaper edition due in Q4; CAICT issued an embodied AI report.
On 16 October 2026, LEADS BIOLABS-B (09887.HK) disclosed first patient enrolment in the open-label, multicentre Phase Ib/II study of Vescuterlimab, a PD-L1/4-1BB bispecific antibody, in combination for metastatic colorectal cancer, led by Academician Xu Ruihua.
In 2026, IDC named DEEPZERO (02723.HK) a Leader in its global B2C enterprise agentic marketing assessment, the only Chinese company selected in the evaluation.
In 2026, IDC named DEEPZERO (02723.HK) a Leader in its first global B2C enterprise agentic marketing assessment, the only Chinese company selected.
On 15 October 2026, VOYAH AUTO (07489.HK) said the CSRC issued a filing notice for its H-share full circulation, covering 1,506,618,471 domestic shares.
On 15 October 2026, CSPC PHARMA (01093.HK) said SYS6062, a monoclonal antibody-drug conjugate, won China clinical trial approval for advanced solid tumours.
On 15 October 2026, CSPC PHARMA (01093.HK) said its PD-1/VEGFA/CTLA-4 trispecific antibody SYS6088 won China nod for advanced/metastatic solid tumour trials.
On October 15, 2026, the HSTECH fell 2.72% and the HSI dropped 1.03%. XIAOMI-W was the only gainer in the pool, up 2.65%, while ILUVATAR COREX fell 13.64%.
In September 2026, IDC named DEEPZERO (02723.HK) a Leader in its global B2C agentic marketing assessment, the only Chinese company; H1 revenue rose 43.6%.
On October 15, 2026, XPENG-W (09868.HK) edged lower. As of 14:25, it was quoted at HK$37.18, down 3.73%.
HUA HONG GRACE (01347.HK) fell 7.16% to HKD 77.100. Sigmaintell expects Q4 fab utilisation of about 91% and 8-inch foundry capacity down about 6% in 2026.
EXCELLAND ROBOT (03231.HK) fell 2.89% to HKD 33.560. Chinese firms took 97% of global humanoid shipments in H1; Morgan Stanley sees USD 5 trillion by 2050.
On 15 October 2026, GENFLEET-B (02595.HK) disclosed progress across studies of oral KRAS G12D inhibitor GFH375/VS-7375, with three Chinese breakthrough therapy designations. Domestic data showed 44% ORR and 89% DCR for GFH375 plus cetuximab in treated CRC, while overseas VS-7375 monotherapy showed 41% cORR in PDAC.
On 14 October 2026, SBP GROUP (01177.HK) said TQ-A3334 data was selected as an AASLD 2026 late-breaking abstract, with Bepirovirsen picked for 10 presentations.
